PIP5K1A: a potential target for cancers with KRAS or TP53 mutations

Nat Rev Drug Discov. 2020 Jul;19(7):436. doi: 10.1038/d41573-020-00067-3.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Drug Development
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Phosphotransferases (Alcohol Group Acceptor) / metabolism*
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Antineoplastic Agents
  • KRAS protein, human
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Phosphotransferases (Alcohol Group Acceptor)
  • 1-phosphatidylinositol-4-phosphate 5-kinase
  • Proto-Oncogene Proteins p21(ras)